• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 20, 2016

View Archived Issues

In the clinic

Pulmatrix Inc., of Lexington, Mass., reported top-line data from a phase I pilot pharmacokinetic (PK) bioavailability trial of PUR0200, a dry powder formulation of a currently marketed once-daily bronchodilator, formulated using the company's Isperse technology, with results supporting continued development of the drug as a potential equivalent of the approved long-acting muscarinic antagonist for the maintenance of bronchospasm in patients with chronic obstructive pulmonary disease in Europe. Read More

Other news to note

Vernalis plc, of Winnersh, U.K., and Suresnes, France-based Les Laboratoires Servier SAS achieved a new milestone in their first oncology drug discovery collaboration, triggering a payment of €500,000 (US$550,750) to Vernalis related to success against an undisclosed target. Read More

Financings

Precision Ocular Ltd., of Oxford, U.K., said V-Bio Ventures had joined investors in the company's series A financing, which has raised £15.5 million (US$20.3 million) in all from investors Imperial Innovations, Consort Medical plc, Neomed and Hovione Scientia Ltd., along with V-Bio. Read More

Potential new target for candidiasis identified

HONG KONG – A collaborative study by U.S. and Chinese researchers has identified an immune system component responsible for the homeostatic control of innate immune responses to nosocomial invasive candidiasis, which represents a potential target that may lead to the development of treatments for the fungal infection. Read More

HTIT, Oramed alliance shows need, challenge of China marketplace

JERUSALEM – Marking a pivotal moment in the growing relationship between China and Israel, the biggest pharma licensing agreement between the two countries recently took another step forward. Jerusalem-based Oramed Pharmaceuticals Inc. received the first milestone payment from its license and investment agreement with Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT), of Hefei, China. Read More

DUX in a row: Fulcrum bid in FSHD, fragile X garners Third Rock $55M series A

Saying "the time is right to bring all the various pieces together," Fulcrum Therapeutics Inc. CEO Robert Gould told BioWorld Today that his firm, funded by a $55 million series A round from Third Rock Ventures LLC, will combine recent findings in the biology of gene regulation to develop small-molecule therapies. Read More

The search for a broadly useful HIV cure continues

DURBAN, South Africa – So far, there has been exactly one person who has been cured of AIDS – Berlin patient Timothy Brown. And his treatment, due to both its dangers and its costs, is definitely not suitable for scale-up. Read More

DODAC members size up suicide risk, side with brodalumab

In a solid win for Valeant Pharmaceuticals International Inc., the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted 18-0 in favor of approving the biologics license application (BLA) for brodalumab, branded Siliq, to treat adults with moderate to severe plaque psoriasis. Read More

Big bounce for Jounce: Firm lands $2.56B Celgene immuno-oncology collaboration

Jounce Therapeutics Inc. will receive a $225 million up-front payment and a $36 million equity investment as part of a five-candidate immuno-oncology (I-O) collaboration with Celgene Corp. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe